
Fast-Track FDA Review Accelerates Path to First Treatment for Alzheimer’s-Related Agitation
Axsome Therapeutics has reached a significant regulatory milestone with the US Food and Drug Administration’s acceptance of a supplemental New Drug Application (NDA) for AXS-05





















